

- 2 Katetrizační ablace renálního sympatiku v roce 2013**
prof. MUDr. Petr Neužil, CSc. | MUDr. Dagmar Vondráková | MUDr. Andrea Chudicová |
MUDr. Simona Michálková | MUDr. Jan Petrů | doc. MUDr. Filip Málek, Ph.D., MBA
Kardiologické oddělení Kardiovaskulárního centra Nemocnice Na Homolce, Praha
- 2 Farmakologická léčba hypertenze**
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika LF MU a FN Brno
prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardio-angiologická klinika, FN u sv. Anny
- 2 Roční zkušenosti kardiovaskulárního centra s dabigatran etexilátem v prevenci tromboembolických příhod u nemocných s fibrilací síní**
doc. MUDr. Miloš Táborský, CSc. | MUDr. František Kováčik | MUDr. Aleš Smékal
I. interní klinika kardiologická FN a LF UP, Olomouc
- 3 Léčba chronického srdečního selhání – doporučení ČKS, srovnání s minulými a evropskými doporučeními**
prof. MUDr. Lenka Špinarová, Ph.D. I. interní kardioangiologická klinika ICRC-FN u sv. Anny a LF MU, Brno
prof. MUDr. Jindřich Špinar, CSc., FESC I. interní kardiologická klinika, FN Brno Bohunice a LF MU Brno
- 4 Vliv frekvence dávkování na adherenci k léčbě u chronických kardiovaskulárních onemocnění**
Craig I. Coleman University of Connecticut School of Pharmacy, Storrs, CT, USA
Matthew S. Roberts | Diana M. Sobieraj University of Connecticut/Hartford Hospital
Evidence-Based Practice Center, Hartford, CT, USA
Craig I. Coleman Hartford Hospital, Hartford, CT, USA
Tawfikul Alam University of Connecticut/Hartford Hospital
Evidence-Based Practice Center, Hartford, CT, USA
Rajbir Kaur Hartford Hospital, Hartford, CT, USAGynekologicko-porodnická klinika 1. LF UK
a Nemocnice Na Bulovce, Praha
- 5 Antikoagulace 2013**
prof. MUDr. Jaroslav Malý, CSc. IV. interní hematologická klinika, LF a FN Hradec Králové
- 6 Antiagregační léčba po revaskularizaci myokardu v roce 2013**
MUDr. Roman Štípal, CSc. | MUDr. David Richter I. interní klinika – kardiologická, Fakultní nemocnice Olomouc
MUDr. Roman Štípal jr. Interní kardiologická klinika Fakultní nemocnice Brno
MUDr. Jiří Ostřanský | MUDr. Marcela Škvařilová, Ph.D. | doc. MUDr. Miloš Táborský, CSc., FESC, MBA
I. interní klinika – kardiologická, Fakultní nemocnice Olomouc
- 7 Léčba dyslipidemií**
doc. MUDr. Michal Vrablík, Ph.D. Centrum preventivní kardiologie, III. Interní klinika 1. LF UK a VFN v Praze
- 8 Nebivolol**
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
- 9 Diagnostický a prognostický význam biomarkerů u pacientů s akutním koronárním syndromem v současné klinické praxi**
MUDr. Petr Kubena Interní kardiologická klinika FN Brno
MUDr. Mgr. Jiří Pařenica, Ph.D. Interní kardiologická klinika FN Brno, LF MU v Brně, Mezinárodní centrum klinického výzkumu –
Klinika kardiovaskulárních onemocnění, FN U sv. Anny v Brně
- 9 Kardioprotektivní léčba u pacientů s esenciální hypertenzí (perindopril + indapamid)**
prof. MUDr. Miroslav Souček, CSc. II. interní klinika LF MU a FN u sv. Anny v Brně
- 10 Kritická končetinová ischemie**
doc. MUDr. Debora Karetová, CSc. | MUDr. Samuel Heller II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha
- 11 Spánková apnoe a ischemická choroba srdeční**
MUDr. Monika Mikolášková | MUDr. Ondřej Ludka, Ph.D. | prof. MUDr. Jindřich Špinar, CSc.
Interní kardiologická klinika FN Brno, Lékařská fakulta Masarykovy univerzity, Brno

Katetrizační ablace renálního sympatiku v roce 2013

prof. MUDr. Petr Neužil, CSc. | MUDr. Dagmar Vondráková | MUDr. Andrea Chudicová |
MUDr. Simona Michálková | MUDr. Jan Petruš | doc. MUDr. Filip Málek, Ph.D., MBA
Kardiologické oddělení Kardiovaskulárního centra Nemocnice Na Homolce, Praha

- 1 Cutler, J. A. – Sorlie, P. D. – Wolz, M. – Thom, T. – Fields, L. E. – Roccella, E. J.: Trends in hypertension prevalence, awareness, treatment and control rates in United States adults between 1988–1994 and 1999–2004. *Hypertension*, 2008, 52, s. 818–827.
- 2 Calhoun, D. A. – Jones, D. – Textor, S., et al.: Resistant hypertension: diagnosis, evaluation and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Circulation*, 2008, 117, s. 510–526.
- 3 Cannon, B.: The effects of progressive sympathectomy on blood pressure. *Amer J Physiol*, 1931, 97, s. 592–596.
- 4 Morrissey, D. M. – Brookes, V. S. – Cooke, W. T.: Sympathectomy in the treatment of hypertension; review of 122 cases. *Lancet*, 1953, 1, s. 403–408.
- 5 Smithwick, R. H. – Thompson, J. E.: Splanchnicectomy for essential hypertension: results in 1,266 cases. *J Am Med Assoc*, 1953, 152, s. 1501–1504.
- 6 Krum, H. – Schlaich, M. – Whitbourn, R. – Sobotka, P. A. – Sadowski, J. – Bartus, K., et al.: Catheter—based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. *Lancet*, 2009, 373, s. 1275–1281.
- 7 Esler, M. D. – Krum, H. – Sobotka, P. A. – Schlaich, M. P. – Schmieder, R. E. – Böhm, M.: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. *Lancet*, 2010, 376, s. 1903–1909.
- 8 Ahmed, H. – Neužil, P. – Petru, J. – Skoda, J. – Sediva, L. – Schejbalova, M. – Reddy, V. Y.: Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for management of drug-resistant hypertension. *JACC Cardiovasc Interv*, 2012, 5, s. 758–765.
- 9 Pokushalov, E. – Romanova, A. – Corbucci, G., et al.: A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. *JACC*, 2012, 60, s. 1163–1170.
- 10 van Jaarsveld, B. C. – Krijnen, P. – Pieterman, H., et al.: The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. *N Engl J Med*, 2000, 342, s. 1007–1014.

Farmakologická léčba hypertenze

prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika LF MU a FN Brno
prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardio-angiologická klinika, FN u sv. Anny

- 1 Filipovský, J. – Widimský, J., jr. – Ceral, J. – Cífková, R. – Horký, K. – Linhart, A. – Monhart, V. – Rosolová, H. – Seidlerová, J. – Souček, M. – Špinar, J. – Vítovec, J. – Widimský, J.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitřní lékařství*, 2012, 58, s. 785–802.
- 2 Filipovský, J. – Widimský, J., jr. – Ceral, J. – Cífková, R. – Horký, K. – Linhart, A. – Monhart, V. – Rosolová, H. – Seidlerová, J. – Souček, M. – Špinar, J. – Vítovec, J. – Widimský, J.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Hypertenze a kardiovaskulární prevence* 2012, 3, s. 1–16.
- 3 Task Force Members 2007. Guidelines for the management of arterial hypertension. *J Hypertension*, 2007, 25, s. 1105–1187.

Roční zkušenosti kardiovaskulárního centra s dabigatran etexilátem v prevenci tromboembolických příhod u nemocných s fibrilací síní

doc. MUDr. Miloš Táborský, CSc. | MUDr. František Kováčik | MUDr. Aleš Smékal
I. interní klinika kardiologická FN a LF UP, Olomouc

- 1 Dewilde, S. – Carey, I. M. – Emma, C., et al.: Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. *Heart*, 2006, 92, s. 1064–1070.
- 2 Camm, A. J. – Kirchhof, P. – Lip, G. Y., et al.: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J*, 2010, 31, s. 2369–2429.
- 3 http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf, vyhlášeno 13. 11. 2012.
- 4 Čihák, R. – Heinc, P. – Haman, L., et al.: Doporučený postup ČKS pro léčbu fibrilace síní. *Cor Vasa*, 2011, 53, s. 27–52.
- 5 Camm, A. J. – Lip, G. Y. H. – De Caterina, R., et al.: 2012 focused update of ESC guidelines for the management of atrial fibrillation. *Eur Heart J*, 2012, 33, s. 2719–2747.
- 6 Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S., et al.: Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 2009, 361, s. 1139–1151.
- 7 Lip, G. Y. H. – Frison, L. – Halperin, J. L., et al.: Identifying patients in high risk of stroke despite anticoagulation. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial

- fibrillation kohort. *Stroke*, 2010, 41, s. 2731–2738.
- 8 Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S., et al.: Newly identified events in the RE-LY trial. *N Engl J Med*, 2010, 363, s. 1875–1876.
 - 9 SPC: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.sjsp&jsenabed=true, vyhledáno 13. 11. 2012.
 - 10 You, J. J. – Singer, D. – Howard, P. A., et al.: Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, 2012, 141, s. 531–575.
 - 11 Husman, M. V., et al.: Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. *Thromb Haemost*, 2012, 107, s. 838–847.
 - 12 Reálky, P. A. – Conrad, C. A. – Fasuj, R. A., et al.: Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial (abstract 129). *Eur Heart J*, 2011, 32, s. 6.
 - 13 Brunet, A. – Hermabessiere, S. – Benain, X.: Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects (abstrakt P3566). *Eur Heart J*, 2011, 32, s. 618–619.
 - 14 Eikelboom, J. – Wallentin, L. – Connolly, S. J., et al.: Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation*, 2011, 123, s. 2363–2672.
 - 15 van Ryn, J. – Litzenburger, T. – Waterman, A., et al.: Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in vitro and in vivo models (abstrakt). *J Am Coll Cardiol*, 2011, 57, s. 1130.
 - 16 Lu, G. – Deguzman, F. R. – Karbarz, M. J., et al.: Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445) (abstrakt 3712). *Eur Heart J*, 2011, 32, s. 640–641.
 - 17 Eerenberg, E. S. – Kamphuisen, P. W. – Sijpkens, M. K., et al.: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. *Circulation*, 2011, 124, s. 1573–1579.
 - 18 CSL Behring Canada Inc. Product monograph Beriplex® P/N (Human prothrombin complex).
 - 19 FDA drug safety communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa. <http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm>, vyhledáno 13. 11. 2012.
 - 20 Hohnloser, S. H. – Oldgren, J. – Yang, S. – Wallentin, L. – Ezekowitz, M. – Reálky, P., et al.: Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. *Circulation*, 2012, 125, s. 669–676.
 - 21 Da Caterina, R. – Husted, S. – Wallentin, L., et al.: New oral anticoagulants in atrial fibrillation and acute coronary syndromes. *J Am Coll Cardiol*, 2012, 59, s. 1413–1425.
 - 22 Nagarakanti, R. – Ezekowitz, M. D. – Oldgren, J., et al.: Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. *Circulation*, 2011, 123, s. 131–136.
 - 23 Dentali, F. – Riva, N. – Crowther, M., et al.: Efficacy of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature. *Circulation*, doi: 10.1161/CIRCULATIONAHA.112.115410, 2012.

Léčba chronického srdečního selhání – doporučení ČKS, srovnání s minulými a evropskými doporučeními

prof. MUDr. Lenka Špinarová, Ph.D.

I. interní kardiologická klinika ICRC-FN u sv. Anny a LF MU, Brno

prof. MUDr. Jindřich Špinar, CSc., FESC I. interní kardiologická klinika, FN Brno Bohunice a LF MU Brno

- 1 McMurray, J. J. – Adamopoulos, S. – Anker, S. D. – Auricchio, A. – Böhm, M. – Dickstein, K. – Falk, V. – Filippatos, G. – Fonseca, C. – Gomez Sanchez, M. A. – Jaarsma, T. – Kober, L. – Lip, G. Z. H. – Maggioni, A. P. – Parkhomenko, A. – Pieske, B. M. – Popescu, B. A. – Ronnevik, P. K. – Rutten, F. H. – Schwitler, J. – Seferovic, P. – Stepinska, J. – Trindade, P. T. – Voors, A. A. – Zannad, F. – Zeiher, A.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J*, 2012, 33, s. 1787–1847.
- 2 Špinar, J. – Vítovec, J. – Hradec, J. – Málek, I. – Meluzín, J. – Špinarová, L. – Hošková, L. – Hegarová, M. – Ludka, O. – Táborský, M.: Czech Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure 2011. *Cor et Vasa*, 2012, 54, s. e114–e134.
- 3 Špinar, J. – Vítovec, J. – Hradec, J. – Málek, I. – Meluzín, J. – Špinarová, L. – Hošková, L. – Hegarová, M. – Ludka, O. – Táborský, M.: Doporučení pro diagnostiku a léčbu chronického srdečního selhání – ČKS 2011. *Cor et Vasa*, 2012, 54, s. 161–182.
- 4 Špinar, J. – Vítovec, J. – Hradec, J. – Málek, I. – Meluzín, J. – Špinarová, L. – Hošková, L. – Hegarová, M. – Ludka, O. – Táborský, M.: Doporučení pro diagnostiku a léčbu chronického srdečního selhání – ČKS 2011. *Vnitřní lékařství*, 2012, 58, s. 4–40.
- 5 Špinarová, L. – Špinar, J. – Vítovec, J.: Novinky v léčbě chronického srdečního selhání – guidelines ČKS 2011, srovnání s minulými doporučeními. *Remedia*, 2012, 2, s. 127–131.

Vliv frekvence dávkování na adherenci k léčbě u chronických kardiovaskulárních onemocnění

Craig I. Coleman University of Connecticut School of Pharmacy, Storrs, CT, USA

Matthew S. Roberts | Diana M. Sobieraj University of Connecticut/Hartford Hospital

Evidence-Based Practice Center, Hartford, CT, USA

Craig I. Coleman Hartford Hospital, Hartford, CT, USA

Tawfikul Alam University of Connecticut/Hartford Hospital

Evidence-Based Practice Center, Hartford, CT, USA

Rajbir Kaur Hartford Hospital, Hartford, CT, USA Gynekologicko-porodnická klinika 1. LF UK

a Nemocnice Na Bulovce, Praha

- 1 **Roger, V. L. – Go, A. S. – Lloyd-Jones, D. M., et al.:** American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. *Circulation*, 2011, 123, e18–209.
- 2 National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US), 2004. Dostupné z: <http://www.nhlbi.nih.gov/guidelines/hypertension> [vyhledáno 8. 11. 2011].
- 3 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*, 2001, 285, s. 2486–2497.
- 4 **Grundey, S. M. – Cleeman, J. I. – Merz, C. N., et al.:** Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *J Am Coll Cardiol*, 2004, 44, s. 720–732.
- 5 **Jessup, M. – Abraham, W. T. – Casey, D. E., et al.:** 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation*, 2009, 119, s. 1977–2016.
- 6 **Choudhry, N. K. – Fischer, M. A. – Avorn, J., et al.:** The implications of therapeutic complexity on adherence to cardiovascular medications. *Arch Intern Med*, 2011, 171, s. 814–822.
- 7 **Claxton, A. J. – Cramer, J. – Pierce, C.:** A systematic review of the associations between dose regimens and medication compliance. *Clin Ther*, 2001, 23, s. 1296–1310.
- 8 **Kalaian, H. A. – Raudenbush, S. W.:** A multivariate mixed linear model for metaanalysis. *Psychological Methods*, 1996, 13, s. 227–235.
- 9 International Society for Pharmacoeconomics and Outcomes Research Website. ISPOR medication compliance and persistence special interest group (MCP). Dostupné z: http://www.ispor.org/signs/mcp_accomplishments.asp [vyhledáno 8. 11. 2011].
- 10 **Baker, W. L. – Cios, D. A. – Sander, S. D., et al.:** Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. *J Manag Care Pharm*, 2009, 15, s. 244–252.
- 11 **Doró, P. – Benkő, R. – Czakov, A., et al.:** Optimal recall period in assessing the adherence to antihypertensive therapy: a pilot study. *Int J Clin Pharm*, 2011, 33, s. 690–695.
- 12 **Kronish, I. M. – Rieckmann, N. – Shimbo, D., et al.:** Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. *Am J Cardiol*, 2010, 106, s. 1090–1094.
- 13 **Platt, A. B. – Localio, A. R. – Brensinger, C. M., et al.:** Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. *Chest*, 2010, 137, s. 883–889.
- 14 **Stille, C. S. – Bender, C. M. – Dunbar-Jacob, J., et al.:** The impact of cognitive function on medication management: three studies. *Health Psychol*, 2010, 29, s. 50–55.
- 15 **Udelson, J. E. – Pressler, S. J. – Sackner-Bernstein, J., et al.:** Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. *J Card Fail*, 2009, 15, s. 385–393.
- 16 **Kardas, P.:** Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. *Vasc Health Risk Manag*, 2007, 3, s. 235–242.
- 17 **Márquez-Contreras, E. – Martell-Claros, N. – Gil-Guillén, V., et al.:** Compliance Group of the Spanish Society of Hypertension (SEE). Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. *J Hypertens*, 2006, 24, s. 169–175.
- 18 **Tu, W. – Morris, A. B. – Li, J., et al.:** Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. *Clin Pharmacol Ther*, 2005, 77, s. 189–201.
- 19 **Girvin, B. G. – Johnston, G. D.:** Comparison of the effects of a 7-day period of noncompliance on blood pressure control using three different antihypertensive agents. *J Hypertens*, 2004, 22, s. 1409–1414.
- 20 **Kardas, P.:** COMPASS Investigators. Comparison of once daily versus twice daily oral nitrates in stable angina pectoris. *Am J Cardiol*, 2004, 94, s. 213–216.
- 21 **Hamilton, G. A.:** Measuring adherence in a hypertension clinical trial. *Eur J Cardiovasc Nurs*, 2003, 2, s. 219–228.
- 22 **Laporte, S. – Quenet, S. – Buchmüller-Cordier, A., et al.:** Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. *Thromb Haemost*, 2003, 89, s. 458–467.
- 23 **Bohachick, P. – Burke, L. E. – Sereika, S., et al.:** Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure. *Prog Cardiovasc Nurs*, 2002, 17, s. 160–166.
- 24 **Girvin, B. – Johnston, G. D.:** A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. *J Hypertens*, 1998, 16, s. 1049–1054.
- 25 **Schwed, A. – Fallab, C. L. – Burnier, M., et al.:** Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. *J Clin Pharmacol*, 1999, 39, s. 402–409.
- 26 **Waeber, B. – Leonetti, G. – Kolloch, R., et al.:** Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. *J Hypertens*, 1999, 17, s. 1041–1045.

- 27 Waeber, B. – Vetter, W. – Darioli, R., et al.: Improved blood pressure control by monitoring compliance with antihypertensive therapy. *Int J Clin Pract*, 1999, 53, s. 37–38.
- 28 Leenen, F. H. – Wilson, T. W. – Bolli, P., et al.: Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. *Can J Cardiol*, 1997, 13, s. 914–920.
- 29 Vrijens, B. – Goetghebeur, E.: Comparing compliance patterns between randomized treatments. *Control Clin Trials*, 1997, 18, s. 187–203.
- 30 Mallion, J. M. – Dutrey-Dupagne, C. – Vaur, L., et al.: Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. *J Hypertens*, 1996, 14, s. 137–144.
- 31 Mason, B.: Anticoagulant clinic warfarin adherence rates and assessment. *J Pharm Technol*, 1996, 12, s. 97–101.
- 32 Straka, R. J. – Fish, J. T. – Benson, S. R., et al.: Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease. *J Clin Pharmacol*, 1996, 36, s. 587–594.
- 33 Brun, J.: Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. *J Int Med Res*, 1994, 22, s. 266–272.
- 34 Kruse, W. – Rampmaier, J. – Ullrich, G., et al.: Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. *Int J Clin Pharmacol Ther*, 1994, 32, s. 452–457.
- 35 Kruse, W. – Nikolaus, T. – Rampmaier, J., et al.: Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. *Eur J Clin Pharmacol*, 1993, 45, s. 211–215.
- 36 Rudd, P. – Ramesh, J. – Bryant-Kosling, C., et al.: Gaps in cardiovascular medication taking: the tip of the iceberg. *J Gen Intern Med*, 1993, 8, s. 659–666.
- 37 Rudd, P. – Ahmed, S. – Zachary, V., et al.: Compliance with medication timing: implications from medication trial for drug development and clinical practice. *J Clin Res Pharmacoevidiol*, 1992, 6, s. 15–27.
- 38 Eisen, S. A. – Miller, D. K. – Woodward, R. S., et al.: The effect of prescribed daily dose frequency on patient medication compliance. *Arch Intern Med*, 1990, 150, s. 1881–1884.
- 39 Eisen, S. A. – Woodward, R. S. – Miller, D., et al.: The effect of medication compliance on the control of hypertension. *J Gen Intern Med*, 1987, 2, s. 298–305.
- 40 Jackevicius, C. A. – Li, P. – Tu, J. V.: Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. *Circulation*, 2008, 117, s. 1028–1036.
- 41 Ho, P. M. – Spertus, J. A. – Masoudi, F. A., et al.: Impact of medication therapy discontinuation on mortality after myocardial infarction. *Arch Intern Med*, 2006, 166, s. 1842–1847.
- 42 Ho, P. M. – Magid, D. J. – Shetterly, S. M., et al.: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. *Am Heart J*, 2008, 155, s. 772–779.
- 43 Farmer, K. C.: Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. *Clin Ther*, 1999, 21, s. 1074–1090.
- 44 Higgins, J. P. T. – Green, S. (eds.): *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [aktualizováno v březnu 2011]. The Cochrane Collaboration, 2011. Dostupné z: www.cochrane-handbook.org [vyhledáno 17. 9. 2011].

Antikoagulace 2013

prof. MUDr. Jaroslav Malý, CSc. IV. interní hematologická klinika, LF a FN Hradec Králové

- 1 Agnelli, G. – Sonaglia, F.: Prevention of venous thrombosis. *Thrombosis Res*, 2000, 97, V49–62.
- 2 Agnelli, G. – Bergqvist, D. – Cohen, A. T. – Gallus, A. S. – Gent, M.: PE-GASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. *Br J Surg*, 2005, 92 (10), s. 1212–1220.
- 3 Aujesky, D. – Roy, P. M. – Verschuren, F. – Righini, M. – Osterwalder, J. – Egloff, M. – Renaud, B. – Verhamme, P. – Stone, R. A. – Lehlo, C. – Sanchez, O. – Pugh, N. A. – N'gako, A. – Cornuz, J. – Hugli, O. – Beer, H. J. – Perrier, A. – Fine, M. J. – Yealy, D. M.: Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. *Lancet*, 2011, 378 (9785), s. 41–48.
- 4 Bathala, M. S. – Masumoto, H. – Oguma, T. – He, L. – Lotrie, C. – Mendell, J.: Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor xa inhibitor, in humans. *Drug Metab Dispos*, 2012, 40, s. 2250–2255.
- 5 Breddin, H. K. – Hach-Wunderle, V. – Nakov, R. – Kalkat, V. V.: For the CORTES Investigators. Effects of a low molecular weight heparin on thrombus regression and recurrent thromboembolism in patients with deep vein thrombosis. *N Engl J Med*, 2001, 344, s. 626–631.
- 6 Büller, H. R. – Davidson, B. L. – Decousus, H. – Gallus, A. – Gent, M. – Piovella, F. – Prins, M. H. – Raskob, G. – Segers, A. E. – Cariou, R. – Leeuwenkamp, O. – Leasing, A. W.: Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. *Ann Intern Med*, 2004, 140 (11), s. 867–873.
- 7 Camm, A. J. – Bounameaux, H.: Edoxaban: a new oral direct factor Xa inhibitor. *Drugs*, 2011, 71, s. 1503–1526.
- 8 Cohen, A. T. – Davidson, B. L. – Gallus, A. S. – Lassen, M. R. – Prins, M. H. – Tomkowski, W. – Turpie, A. G. – Egberts, J. F. – Lensing, A. W.: ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *BMJ*, 2006, 11, 332 (7537), s. 325–329.
- 9 Cohen, A. T. – Spiro, T. E. – Büller, H. R. – Haskell, L. – Hu, D. – Hull, R. – Mebazaa, A. – Merli, G. – Schellong, S. – Spyropoulos, A. – Tapon, V.: Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. *J Thromb Thrombolysis*, 2011, 31 (4), s. 407–416.
- 10 Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S. – Eikelboom, J., et al.: RE-LY steering committee and investigators: dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 2009, 361 (12), s. 1139–1151.
- 11 Decousus, H. – Prandoni, P. – Mismetti, P. – Bauersachs, R. M. – Boda, Z. – Brenner, B. – Laporte, S. – Matyas, L. – Middeldorp, S. – Sokenko, G. – Leizorovicz, A.: CALISTO Study Group. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. *N Engl J Med*, 2010, 363 (13), 1222v32.
- 12 EINSTEIN Investigators, Bauersachs, R. – Berkowitz, S. D. – Brenner, B. – Bulle, H. R. – Decousus, H. – Gallus, A. S. – Leasing, A. W. – Misselwitz, F. – Prins, M. H. – Raskob, G. E. – Segers, A. – Verhamme, P. – Wells, P. – Agnelli, G. – Bounameaux, H. – Cohen, A. – Davidson, B. L. – Piovella, F. – Schellong, S.: Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*, 2010, 363 (26), s. 2499–2510.
- 13 EINSTEIN-PE Investigators, Büller, H. R. – Prins, M. H. – Lensin, A. W. – Decousus, H. – Jacobson, B. F. – Minar, E. – Chlumsky, J. – Verhamme, P. – Wells, P. – Agnelli, G. – Cohen, A. – Berkowitz, S. D. – Bounameaux, H. – Davidson, B. L. – Misselwitz, F. – Gallus, A. S. – Raskob, G. E. – Schellong, S. – Segers, A. N.: Oral rivaroxaban for the treatment

- of symptomatic pulmonary embolism. *N Engl J Med*, 2012, 5, 366 (14), s. 1287–1297.
- 14 Ericsson, B. I. – Dahl, O. E. – Rosencher, N., et al.: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thromb Haemost*, 2007, 5, s. 2178–2185.
 - 15 Gibbon, C. M. – Mega, J. L. – Buton, P. – Goto, S. – Verheugt, F. – Bode, C. – Plotnikov, A. – Sun, X. – Cook-Bruns, N. – Braunwald, E.: Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. *Am Heart J*, 2011, 161 (5), s. 815–821.
 - 16 Gustafsson, D.: Oral direct thrombin inhibitors in clinical development. *J Intern Med*, 2003, 254, s. 322–334.
 - 17 Guyatt, G. H. – Akl, E. A. – Crowther, M. – Gutterman, D. D. – Schünemann, H. J.: Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. *Chest*, 2012, 141 (dopl. 2), s. 75–475.
 - 18 Hull, R. D. – Raskob, G. E. – Brant, R. F., et al.: Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. *Arch Intern Med*, 2000, 160, s. 229–236.
 - 19 Karetová, D. – Bultas, J.: Nová antikoagulancia v prevenci a léčbě kardiiovaskulárních chorob. *Postgraduální medicína*, 2010, 1, s. 72–77.
 - 20 Lassen, M. R. – Ageno, W. – Borris, L. C. – Lieberman, J. R. – Rosencher, N. – Bandel, T. J. – Misselwitz, F. – Turpie, A. G.: RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *Engl J Med*, 2008, 358 (26), s. 2776–2786.
 - 21 Levine, M. – Gent, M. – Hirsh, J., et al.: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med*, 1996, 334, s. 677–681. Turpie, A. G.: Choice of low molecular weight heparins. *J Thromb Haemost*, 2003, 1, s. 598.
 - 22 Oldgren, J. – Budaj, A. – Granger, C. B. – Khder, Y. – Roberts, J. – Siegbahn, A. – Tijssen, J. G. – Van de Werf, F. – Wallentin, L.: RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J*, 2011, 32 (22), s. 2781–2789.
 - 23 ROCKET AF Study Investigators: Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. *Am Heart J*, 2010, 159 (3), s. 340–347.
 - 24 Schulman, S.: Treatment of venous thromboembolism with dabigatran. *Curr Opin Pulm Med*, 2012, 18 (5), s. 410–415.
 - 25 Turpie, A. G. – Norris, T. M.: Thromboprophylaxis in medical patients, the role of low-molecular-weight heparin. *Thromb Haemost*, 2004, 92, s. 3–12.
 - 26 Turpie, A. G. – Bauer, K. A. – Ericsson, B. I. – Larsen, M. R.: Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Arch Intern Med*, 2002, 162 (16), s. 1833–1840.
 - 27 Van Ryn, J. – Stangier, J. – Haertter, S. et al.: Dabigatran etexilate a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. *Thromb Haemost*, 2010, 103, s. 1116–1127.

Antiagregační léčba po revaskularizaci myokardu v roce 2013

MUDr. Roman Štípal, CSc. | MUDr. David Richter I. interní klinika – kardiologická, Fakultní nemocnice Olomouc
 MUDr. Roman Štípal jr. Interní kardiologická klinika Fakultní nemocnice Brno
 MUDr. Jiří Ostřanský | MUDr. Marcela Škvařilová, Ph.D. | doc. MUDr. Miloš Táborský, CSc., FESC, MBA I. interní klinika – kardiologická, Fakultní nemocnice Olomouc

- 1 Theroux, P. – Ouimet, H. – McCans, J., et al.: Aspirin, heparin, or both to treat acute unstable angina. *N Engl J Med*, 1988, 319, s. 1105–1111.
- 2 Theroux, P. – Waters, D. – Qui, S., et al.: Aspirin versus heparin to prevent myocardial infarction during acute phase of unstable angina. *Circulation*, 1993, 88, s. 2045–2048.
- 3 Baigent, C. – Blackwell, L. – Collins, R., et al.: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*, 2009, 373, s. 1849–1860.
- 4 Mehta, S. R. – Tanguay, J. F. – Eikelboom, J. W., et al.: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *Lancet*, 2010, 376, s. 1233–1243.
- 5 Gislason, G. H. – Jacobsen, S. – Rasmussen, J. N., et al.: Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroid antiinflammatory drugs after acute myocardial infarction. *Circulation*, 2006, 113, s. 2906–2913.
- 6 Yusuf, S. – Zhao, F. – Mehta, S. R., et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*, 2001, 345, s. 494–502.
- 7 Snoep, J. D. – Hovens, M. M. – Eikenboom, J. C., et al.: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. *Am Heart J*, 2007, 154, s. 221–231.
- 8 The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med*, 2010, 363, s. 930–942.
- 9 Taubert, D. – von Beckerath, N. – Grimberg, G., et al.: Impact of P-glycoprotein on clopidogrel absorption. *Clin Pharmacol Ther*, 2006, 80, s. 486–501.
- 10 Wiviott, S. D. – Trenk, D. – Frelinger, A. L., et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial. *Circulation*, 2007, 116, s. 2923–2932.
- 11 Wiviott, S. D. – Braunwald, E. – McCabe, C., et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*, 2007, 357, s. 2001–2015.
- 12 Gurbel, P. A. – Blinden, K. P. – Butler, K., et al.: Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study. *Circulation*, 2009, 120, s. 2577–2585.
- 13 Wallentin, L. – Becker, R. C. – Budaj, A., et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*, 2009, 361, s. 1045–1057.
- 14 Hamm, C. W. – Bassand, J. P. – Agewall, S., et al.: ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*, 2011, 32, s. 2999–3054.

- 15 Bhatt, D. I. – Stone, G. W. – Mahaffey, K. W., et al.: Effect of platelet inhibition with cangrelor during PCI on ischemic events. *N Engl J Med*, 2013, doi:10.1056/NEJMoa1300615.
- 16 Van de Werf, F. – Bax, J. – Betriu, A., et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. *Eur Heart J*, 2008, 29, s. 2909–2945.
- 17 Montalescot, G. – Wiviott, S. D. – Braunwald, E., et al.: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. *Lancet*, 2009, 373, s. 723–731.
- 18 Cannon, C. P. – Harrington, R. A. – James, S., et al.: Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. *Lancet*, 2010, 375, s. 283–293.
- 19 Wijns, W. – Kolh, P. – Danchin, N., et al.: Guidelines on myocardial revascularization. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*, 2010, 31, s. 2501–2555.
- 20 O’Gara, P. T. – Kushner, F. D. – Ascheim, D. D., et al.: 2013 ACCF/AHA guidelines for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*, 2013, 61, s. 485–510.
- 21 Kala, P. – Němec, P. – Želízko, M., et al.: Doporučené postupy pro revaskularizaci myokardu. *Cor Vasa*, 2011, 53, dopl. 1.
- 22 Kirtane, A. – Silber, S. – Neumann, F. J., et al.: The relationship between short and long-term antiplatelet therapy use and stent thrombosis following percutaneous coronary intervention with the Resolute zotarolimus-eluting stent. *J Am Coll Cardiol*, 2013, 61, s. 10, doi: 10.1016/S0735-1097(13)61862-8).
- 23 Abbott’s Xience Prime and Xience V drug eluting stents receive indication in Europe for minimum three-month duration of dual anti-platelet therapy. Paříž, 15. 5. 2012, www.AbbottVascular.com.
- 24 Head, S. J. – Bogers, J. J. C. – Kappetein, P.: New anticoagulants in cardiac surgery. *Interventional Cardiology*, 2011, 1, s. 71–75.
- 25 Fox, K. A. – Mehta, S. R. – Peters, R., et al.: Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. *Circulation*, 2004, 110, s. 1202–1208.
- 26 Held, C. – Asenblad, N. – Bassand, J. P., et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery results from the PLATO Trial. *J Am Coll Cardiol*, 2011, 57, s. 672–684.
- 27 Čihák, R. – Heinc, P. – Haman, J., et al.: Fibrilace síní. Doporučené postupy u pacientů s fibrilací síní. *Cor Vasa*, 2011, 53, dopl. 1.
- 28 Dewilde, W. J. M. – Oirbans, T. – Verheugt, F. W. A., et al.: Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet*, 2013, 381, s. 1107–1115.
- 29 Angiolillo, D. J. – Firstenberg, M. S. – Price, M. J., et al.: Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. *JAMA*, 2012, 307, s. 265–274.

Léčba dyslipidemií

doc. MUDr. Michal Vrablík, Ph.D.

Centrum preventivní kardiologie, III. Interní klinika 1. LF UK a VFN v Praze

- 1 Ústav zdravotnických informací: *Zdravotnická statistika. Zemřelí 2011*. Dostupné na www.uzis.cz.
- 2 Cífková, R. – Škodová, Z. – Bruthans, J., et al.: Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. *Atherosclerosis*, 2010, 211, s. 676–681.
- 3 Vrablík, M., et al.: Otazníky kardiovaskulární prevence 2009. *FAMA*, Brno, 2009, s. 187.
- 4 Catapano, A. L. – Reiner, Z. – De Backer, G., et al.: ESC/EAS Guidelines for the management of dyslipidaemias. *Atherosclerosis*, 2011, 217, s. 3–46.
- 5 Vaverková, H. – Soška, V. – Rosolová, H., et al.: Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výběrem České společnosti pro aterosklerózu. *Vnitřní Lékař*, 2007, 53, s. 181–197.
- 6 Perk, J. – Backer, G. D. – Gohlke, H., et al.: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. *Eur J Prev Cardiol*, 2012, 19, s. 585–667.
- 7 Češka, R., et al.: *Cholesterol a ateroskleróza – léčba dyslipidemií*. Triton, Praha, 2012, s. 408.
- 8 HPS THRIVE collaborative group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. *Eur Heart J*, 2013, doi:10.1093/eurheartj/ehs055.
- 9 Armitage, J. – Bowman, L. – Wallendszus, K., et al.: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet*, 2010, 376, s. 1658–1669.
- 10 Rajpathak, S. N. – Kumbhani, D. J. – Crandall, J., et al.: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. *Diabetes Care*, 2009, 32, s. 1924–1929.
- 11 Preiss, D. – Sattar, N.: Statins and the risk of new-onset diabetes: a review of recent evidence. *Curr Opin Lipido*, 2011, 22, s. 460–466.
- 12 Ridker, P. M. – Pradhan, A. – MacFadyen, J. G. – Libby, P., et al.: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet*, 2012, 380, s. 565–571.
- 13 Belalcazar, L. M. – Raghavan, V. A. – Ballantyne, C. M.: Statin-induced diabetes: will it change clinical practice? *Diabetes Care*, 2009, 32, s. 1941–1943.
- 14 Ginsberg, H. N. – Elam, M. B. – Lovato, L. C., et al.: ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*, 2010, 362, s. 1563–1574.
- 15 Sacks, F. M. – Carey, V. J. – Fruchart, J. C.: Combination lipid therapy in type 2 diabetes. *N Engl J Med*, 2010, 363, s. 692–694.
- 16 Wright, A. D. – Dodson, P. M.: Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. *Eye (Lond)*, 2011, 25, s. 843–849.
- 17 Boden, W. E. – Probstfield, J. L. – Anderson, T., et al.: AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*, 2011, 365, s. 2255–2267.
- 18 Davidson, M. H. – Ballantyne, C. M. – Kerzner, B., et al.: Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. *Int J Clin Pract*, 2004, 58, s. 746–755.
- 19 Baigent, C. – Landray, M. J. – Reith, C., et al.: SHARP Investigators.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*, 2011,

377, s. 2181–2192.

20 **Shepherd, J.**: Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. *Cardiology*, 1989, 76, s. 65–71.

Nebivolol

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

- 1 **Rousselín, Y.** – **Bruel, A.** – **Clavel, A.**: (S,S,S) – Nebivolol hydro-chloride hemihydrate. *Acta Crystallogr Sect E Struct Rep Online*, 2012, 68, s. 3352.
- 2 **Feng, M. G.** – **Prieto, M. C.** – **Navar, L. G.**: Nebivolol-induced vasodilation of renal afferent arterioles involves beta3-adrenergic receptor and nitric oxide synthase activation. *Am J Physiol Renal Physiol*, 2012, 303, s. F775–F782.
- 3 **Garban, H. J.** – **Buga, G. M.** – **Ignarro, L. J.**: Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. *J Cardiovasc Pharmacol*, 2004, 43, s. 638–644.
- 4 **Aragon, J. P.** – **Condit, M. E.** – **Bhushan, S.**, et al.: Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. *J Am Coll Cardiol*, 2011, 58, s. 2683–2691.
- 5 **Moningka, N. C.** – **Tsarova, T.** – **Sasser, J. M.** – **Baylis, C.**: Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade. *Nephrol Dial Transplant*, 2012, 27, s. 913–920.
- 6 **Toblli, J. E.** – **DiGennaro, F.** – **Giani, J. F.** – **Dominici, F. P.**: Nebivolol: impact on cardiac and endothelial function and clinical utility. *Vasc Health Risk Manag*, 2012, 8, s. 151–160.
- 7 **Manrique, C.** – **Lastra, G.** – **Habibi, J.**, et al.: Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. *Metabolism*, 2011, 60, s. 1757–1766.
- 8 **Gunes, Y.** – **Gumrukcuoglu, H. A.** – **Akdag, S.** – **Simsek, H.** – **Sahin, M.** – **Tuncer, M.**: Vascular endothelial function in patients with coronary slow flow and the effects of nebivolol. *Arq Bras Cardiol*, 2011, 97, s. 275–280.
- 9 **Varagic, J.** – **Ahmad, S.** – **Voncannon, J. L.**, et al.: Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. *J Hypertens*, 2012, 30, s. 1766–1774.
- 10 **Serg, M.** – **Kampus, P.** – **Kals, J.**, et al.: Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. *Scand J Clin Lab Invest*, 2012, 72, s. 427–432.
- 11 **Soanker, R.** – **Naidu, M. U.** – **Raju, S. B.** – **Prasad, A. K.** – **Rao, T. R.**: Effect of beta-1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension. *Indian J Pharmacol*, 2012, 44, s. 407–411.
- 12 **Brixius, K.** – **Bundkirchen, A.** – **Bolck, B.** – **Mehlhorn, U.** – **Schwinger, R. H.**: Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. *Br J Pharmacol*, 2001, 133, s. 1330–1338.
- 13 **Cheema, Y.** – **Sherrod, J. N.** – **Zhao, W.**, et al.: Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol. *J Cardiovasc Pharmacol*, 2011, 58, s. 80–86.
- 14 **Kamp, O.** – **Metra, M.** – **Bugatti, S.**, et al.: Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. *Drugs*, 2010, 70, s. 41–56.
- 15 **Kamp, O.** – **Sieswerda, G. T.** – **Visser, C. A.**: Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. *Am J Cardiol*, 2003, 92, s. 344–348.
- 16 **Grassi, G.** – **Trevano, F. Q.** – **Facchini, A.** – **Toutouzas, T.** – **Chanu, B.** – **Mancia, G.**: Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. *Blood Press Suppl*, 2003, 2, s. 35–40.
- 17 **Van Bortel, L. M.** – **Fici, F.** – **Mascagni, F.**: Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs*, 2008, 8, s. 35–44.
- 18 **Edes, I.** – **Gasior, Z.** – **Wita, K.**: Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. *Eur J Heart Fail*, 2005, 7, s. 631–639.
- 19 **Flather, M. D.** – **Shibata, M. C.** – **Coats, A. J.**, et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J*, 2005, 26, s. 215–225.
- 20 **Chatterjee, S.** – **Biondi-Zoccai, G.** – **Abbate, A.**, et al.: Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. *BMJ*, 2013, 346, s. f55.
- 21 **Aksoy, S. M.** – **Cay, S.** – **Cagirci, G.** – **Sen, N.**: Nebivolol therapy improves QTC and QTcd parameters in heart failure patients. *Cardiovasc J Afr*, 2012, 23, s. 191–193.
- 22 **Badar, V. A.** – **Hiware, S. K.** – **Shrivastava, M. P.** – **Thawani, V. R.** – **Hardas, M. M.**: Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. *Indian J Pharmacol*, 2011, 43, s. 437–440.
- 23 **Celik, T.** – **Ilysoy, A.** – **Kursaklioglu, H.**, et al.: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. *J Hypertens*, 2006, 24, s. 591–596.
- 24 **Agabiti, R. E.** – **Rizzoni, D.**: Metabolic profile of nebivolol, a beta-adrenoreceptor antagonist with unique characteristics. *Drugs*, 2007, 67, s. 1097–1107.
- 25 **Ayers, K.** – **Byrne, L. M.** – **DeMatteo, A.** – **Brown, N. J.**: Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. *Hypertension*, 2012, 59, s. 893–898.
- 26 **Schmidt, A. C.** – **Graf, C.** – **Brixius, K.** – **Scholze, J.**: Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. *Clin Drug Investig*, 2007, 27, s. 841–849.
- 27 **Cleophas, T. J.** – **Agrawal, R.** – **Lichtenthal, A.** – **Makel, W.** – **Fici, F.**: Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. *Am J Ther*, 2006, 13, s. 192–197.
- 28 **Brixius, K.** – **Middeke, M.** – **Lichtenthal, A.** – **Jahn, E.** – **Schwinger, R. H.**: Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. *Clin Exp Pharmacol Physiol*, 2007, 34, s. 327–331.

Diagnostický a prognostický význam biomarkerů u pacientů s akutním koronárním syndromem v současné klinické praxi

MUDr. Petr Kubena Interní kardiologická klinika FN Brno

MUDr. Mgr. Jiří Pařenica, Ph.D. Interní kardiologická klinika FN Brno, LF MU v Brně, Mezinárodní centrum klinického výzkumu – Klinika kardiovaskulárních onemocnění, FN U sv. Anny v Brně

- 1 Thygesen, K. – Alpert, J. S. – Jaffe, A. S., et al.: Third universal definition of myocardial infarction. *J Am Coll Cardiol*, 2012, 60, s. 1581–1598.
- 2 Giannitsis, E. – Kurz, K. – Hallermayer, K., et al.: Analytical validation of a high-sensitivity cardiac troponin T assays. *Clin Chem*, 2010, 56, s. 254–261.
- 3 Troponin T hs. Elecsys and cobas e analyzers, dostupné z: http://www.rochecanada.com/fmfiles/re7234008/package_inserts/TROPO-NINTHS-05092744190-ENGLISH-V4-CAN.pdf [cit. 31. 3. 2013].
- 4 Morrow, D. A. – Cannon, C. P. – Jesse, R. L., et al.: Clinical characteristics and utilization of biochemical markers in acute coronary syndrome. *Clin Chem*, 2007, 53, s. 552–574.
- 5 Bueno, H. – Avilés, F. F.: Use of risk scores in acute coronary syndromes. *Heart*, 2012, 98, s. 162–168.
- 6 Hallén, J. – Buser, P. – Schwitzer, J., et al.: Relation of cardiac troponin I measurements at 24 and 48 hours to magnetic resonance-determined infarct size in patients with ST-elevation myocardial infarction. *Am J Cardiol*, 2009, 104, s. 1472–1477.
- 7 Kurz, K. – Giannitsis, E. – Becker, M., et al.: Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. *Clin Res Cardiol*, 2011, 100, s. 209–215.
- 8 Myoglobin Gen. 2. Roche/Hitachi, dostupné z: <http://www.roche-diagnostics.cz/objednavky/info/04579976p.pdf> [cit. 31. 3. 2013].
- 9 Collinson, P. O. – Stubbs, P. J. – Kessler, A. C.: Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice. *Heart*, 2003, 89, s. 280–286.
- 10 Eggers, K. M. – Oldgren, J. – Nordenskjöld, A., et al.: Diagnostic value of serial measurement of cardiac markers in patients with chest pain: Limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. *Am Heart J*, 2004, 148, s. 574–581.
- 11 CK-MB: Roche/Hitachi, dostupné z: <http://www.roche-diagnostics.cz/objednavky/info/03012468p.pdf> [cit. 31. 3. 2013].
- 12 Christenson, R. H. – Vaidya, H. – Landt, Y., et al.: Standardization of creatine kinase-MB (CK-MB) mass assays: The use of recombinant CK-MB as a reference material. *Clin Chem*, 1999, 45, s. 1414–1423.
- 13 Friedecký, B. – Engliš, M., et al.: Doporučení České společnosti klinické biochemie ke stanovení biochemických markerů poškození myokardu. *Klin Biochem Metab*, 2008, 37, s. 50–55.
- 14 Weber, M. – Mitrovic, V. – Hamm, C.: B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide—diagnostic role in stable coronary artery disease. *Exp Clin Cardiol*, 2006, 11, s. 99–101.
- 15 Hama, N. – Itoh, H. – Shirakami, G., et al.: Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. *Circulation*, 1995, 92, s. 1558–1564.
- 16 Kragelund, C. – Grønning, B. – Køber, L., et al.: N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. *N Engl J Med*, 2005, 352, s. 666–675.
- 17 Mayr, A. – Mair, J. – Schocke, M., et al.: Predictive value of NT-pro BNP after acute myocardial infarction: Relation with acute and chronic infarct size and myocardial function. *Int J Cardiol*, 2011, 147, s. 118–123.
- 18 Morrow, D. A. – de Lemos, J. A. – Sabatine, M. S., et al.: Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non-ST-elevation myocardial infarction B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. *J Am Coll Cardiol*, 2003, 41, s. 1264–1272.
- 19 Armstrong, E. J. – Morrow, D. A. – Sabatine, M. S.: Inflammatory biomarkers in acute coronary syndromes part II: Acute-phase reactants and biomarkers of endothelial cell activation. *Circulation*, 2006, 113, s. e152–e155.
- 20 Lindberg, S. – Pedersen, S. H. – Mogelvang, R., et al.: Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *J Am Coll Cardiol*, 2012, 60, s. 339–345.
- 21 Pepys, M. B. – Hirschfield, G. M.: C-reactive protein: a critical update. *J Clin Invest*, 2003, 111, s. 1805–1812.
- 22 Hamm, Ch. W. – Bassand, J. P. – Agewall, S., et al.: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*, 2011, 32, s. 2999–3054.
- 23 Schiele, F. – Meneveau, N. – Seronde, M. F., et al.: C-reactive protein improves risk prediction in patients with acute coronary syndromes. *Eur Heart J*, 2010, 31, s. 290–297.
- 24 Schneider, H. G. – Lam, Q. T.: Procalcitonin for the clinical laboratory: a review. *Pathology*, 2007, 39, s. 383–390.
- 25 McCann, C. J. – Glover, B. M. – Menown, I. B., et al.: Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. *Eur Heart J*, 2008, 29, s. 2843–2850.

Kardioprotektivní léčba u pacientů s esenciální hypertenzí (perindopril + indapamid)

prof. MUDr. Miroslav Souček, CSc. II. interní klinika LF MU a FN u sv. Anny v Brně

- 1 Lancia, G., et al.: 2007 Guidelines for the management of arterial hypertension. *Eur Heart J*, 2007, 28, s. 1462–1536.
- 2 Reid, I. A.: The renin-angiotensin system and body function. *Arch Intern Med*, 1985, 145, s. 1475.
- 3 Dahlöf, B. – Sever, P. S. – Poulter, N. E., et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). *Lancet*, 2005, 366, s. 895–906.
- 4 PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6 105 patients with prior stroke or transient ischaemic attack. *Lancet*, 2001, 358, s. 1033–1041.
- 5 ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular

- outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*, 2007, 370, s. 829–840.
- 6 The EUROPEAN trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*, 2003, 362, s. 782–788.
 - 7 Speirs, C. – Wagniar, F. – Poggi, L.: Perindopril post marketing surveillance: a 12 month study in 47,351 hypertensive patients. *Br J Clin Pharmacol*, 1998, 46 (1), s. 63–70.
 - 8 Clark, L. T.: Safety profile of perindopril. *Am J Cardiol*, 2001, 88 (7A), s. 36i–40i.
 - 9 Bots, M. I. – Remme, W. J. – Lüsche, T. F., et al.: ACE inhibition and endothelial function: main findings of PERFECT. A sub-study of the EUROPA trial. *Cardiovasc Drugs Ther*, 2007, 21, s. 269–279.
 - 10 Ceconi, C. – Fox, K. M., et al.: ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. *Cardiovasc Research*, 2007, 73, s. 237–246.
 - 11 Rodriguez-Granillo, G. A. – Vos, J. – De Feyter, P. D.: Long-term effect of perindopril on coronary atherosclerosis progression (from the Perindopril's Prospective Effect on Coronary Atherosclerosis by Angiography and Intravascular Ultrasound Evaluation (PERSPECTIVE) Study). *Am J Cardiol*, 2007, 100, s. 159–163.
 - 12 Ferrari, R. – Pasanisi, G. – Notarstefano, P., et al.: Specific properties and effect of perindopril in controlling the renin-angiotensin system. *Am J Hypertens*, 2005, 18 (9 Pt 2), s. 142S–154S.
 - 13 Brugts, J. J., et al.: The consistency of the treatment effect of an angiotensin-converting enzyme-inhibitor-based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials comparing perindopril–indapamide vs. placebo. *Eur Heart J*, 2009, 30, s. 1358–1394.
 - 14 Rosolová, H.: Diuretika a jejich fixní kombinace: mýty a fakta. *Medical Tribune*, 2012, 12.
 - 15 Filipovský, J.: Postavení diuretik v léčbě hypertenze. In: *Arteriální hypertenze – současné klinické trendy X*. Triton, 2012, s. 129–138.
 - 16 Baguet, J. P. – Robitail, S. – Boyer, L., et al.: A metaanalytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. *Am J Cardiovasc Drugs*, 2005, 5, s. 131–140.
 - 17 London, G. – Schmieder, R. – Calvo, C., et al.: Indapamid SR versus candesartan and amlodipin in hypertension: X-CELLENT Study. *Am J Hypertens*, 2006, 19, s. 113–121.
 - 18 Gosse, P. – Sheridan, D. J. – Zannad, F., et al.: Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg; the LIVE study. *J Hypertens*, 2000, 18, s. 1465–1475.
 - 19 Madkour, H., et al.: comparison between the effects of indapamide and hydrochlorothiazide on kreatinine clearance in patients with impaired renal function and hypertension. *Am J Nephrol*, 1995, 15 (3), s. 251–255.
 - 20 Emeriau, J. P., et al.: A comparison of indapamide SR 1,5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. *J Hypertens*, 2001, 19 (2), s. 343–350.
 - 21 Hannson, L. – Zanchetti, A. – Carruthers, S. G., et al.: Effect of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized Trial. *Lancet*, 1998, 351, s. 1755–1762.
 - 22 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *Br Med J*, 1998, 317, s. 703–713.
 - 23 Beckett, N. S. – Peters, R. – Fletcher, A. E., et al., for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–1898.

Kritická končetinová ischemie

doc. MUDr. Debora Karetová, CSc. | MUDr. Samuel Heller

II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

- 1 Sigvant, B. – Wiberg-Hedman, K. – Bergqvist, D., et al.: A population based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex difference. *J Vasc Surg*, 2007, 45, s. 1185–1191.
- 2 Arvela, E. – Venermo, M. – Söderström, M., et al.: Infringuinal percutaneous transluminal angioplasty or bypass surgery in patients aged 80 years and older with critical limb ischemia. *Br J Surg*, 2011, 98, s. 518–526.
- 3 Adam, D. J. – Beard, J. D. – Cleveland, T., et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet*, 2005, 366, s. 1925–1934.
- 4 Taylor, G. I. – Palmer, J. H. – Seville, R. F. – Attinger, C. E. – Bulan, E. J., et al.: Revascularization of a specific angiosome for limb salvage: does the target artery matter? *Ann Vasc Surg*, 2009, 23, s. 367–373.
- 5 Peregrin, J. H. – Kožnar, B.: PTA of infrapopliteal arteries: Long-term clinical follow-up and analysis of factors influencing clinical outcome. *Cardiovasc Intervent Radiol*, 2010, 33, s. 720–725.
- 6 Norgren, L. – Hiatt, W. – Dormandy, J., et al.: Intersociety consensus for the management of peripheral arterial disease (TASC II). *Eur J Vasc Endovasc Surg*, 2007, 33, s. 1–75.
- 7 Albers, M. – Romiti, M. – Brochado-Neto, F. C., et al.: Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. *Vasc Surg*, 2006, 43, s. 498–503.
- 8 Lenk, K. – Adams, V. – Lurz, P., et al.: Therapeutic potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. *Eur Heart J*, 2005, 26, s. 1903–1909.

Spánková apnoe a ischemická choroba srdeční

MUDr. Monika Mikolášková | MUDr. Ondřej Ludka, Ph.D. | prof. MUDr. Jindřich Špinar, CSc.

Interní kardiologická klinika FN Brno, Lékařská fakulta Masarykovy univerzity, Brno

- 1 Somers, V. K. – White, D. P. – Amin, R., et al.: Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. *J Am Coll Cardiol*, 2008, 52 (8), s. 686–717.
- 2 Young, T. – Palta, M. – Dempsey, J., et al.: The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med*, 1993, 328, s. 1230–1235.
- 3 Wolk, R. – Kara, T. – Somers, V. K.: Sleep-disordered breathing and cardiovascular disease. *Circulation*, 2003, 108 (1), s. 9–12.
- 4 Šonka, K. – Slonková, J.: Spánková apnoe dospělého věku. *Cesk Slov Neurol N*, 2008, 71/104 (6), s. 643–656.
- 5 Šonka, K. – Jakoubková, M. – Paul, K.: Vyšetřování poruch spánku a bdění. In: Nevšímalová, S. – Šonka, K. (eds). *Poruchy spánku a bdění*. Praha, Galén, 2007, s. 59–86.
- 6 Kato, M. – Adachi, T. – Koshino, U., et al.: Obstructive sleep apnea and cardiovascular disease. *Circ J*, 2009, 73, s. 1363–1370.
- 7 Jelic, S. – Le Jemtel, T. H.: Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea. *Trends Cardiovasc Med*, 2008, 18, s. 253–260.
- 8 Mary, S. M. – Tse, H. F. – Lam, B., et al.: Endothelial function in obstructive sleep apnea and response to treatment. *Am J Respir Crit Care Med*, 2004, 169, s. 348–353.
- 9 Lavie, L. – Lavie, P.: Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. *Eur Respir J*, 2009, 33, s. 1467–1484.
- 10 Von Känel, R. – Loredo, J. S. – Ancoli-Israel, S., et al.: Association between polysomnographic measures of disrupted sleep and prothrombotic factors. *Chest*, 2007, 131, s. 733–739.
- 11 Shahar, E. – Whitney, C. W. – Redline, S., et al.: Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *Am J Respir Crit Care Med*, 2001, 163, s. 19–25.
- 12 Turmel, J. – Sériés, F. – Boulet, L. P., et al.: Relationship between atherosclerosis and the sleep apnea syndrome: an intravascular ultrasound study. *Int J Cardiol*, 2009, 132, s. 203–209.
- 13 Sorajja, D. – Gami, A. S. – Somers, V. K., et al.: Independent association between obstructive sleep apnea and subclinical coronary artery disease. *Chest*, 2008, 133, s. 927–933.
- 14 Yumino, D. – Tsurumi, Y. – Takagi, A., et al.: Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. *Am J Cardiol*, 2007, 99, s. 26–30.
- 15 Nakashima, H. – Katayama, T. – Takagi, Ch., et al.: Obstructive sleep apnoea inhibits the recovery of left ventricular function in patients with acute myocardial infarction. *European Heart Journal*, 2006, 27, s. 2317–2322.
- 16 Gottlieb, D. J. – Yenokyan, G. – Newman, A. B., et al.: Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: The Sleep Heart Health Study. *Circulation*, 2010, 122, s. 352–360.
- 17 Sert Kuniyoshi, F. H. – Garcia-Touchard, A. – Gami, A. S., et al.: Day-night variation of acute myocardial infarction in obstructive sleep apnea. *J Am Coll Cardiol*, 2008, 52, s. 343–346.